Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy (PTCRRT)

Toulouse University Hospital

Status and phase

Completed

Phase 4

Conditions

Body Clearance

Piperacillin Tazocilline Concentrations (Cmin)

Diffusive and Convective Clearance

Treatments

Drug: piperacillin/tazobactam

Procedure: Pharmacokinetic

Study type

Interventional

Funder types

Other

Identifiers

NCT00703144

07 300 02

University Hospital Toulouse

Details and patient eligibility

About

The pharmacokinetics of piperacillin/tazobactam will be evaluated in twenty septic patients with renal failure undergoing continuous veno-venous hemodiafiltration.

Full description

The pharmacokinetics of piperacillin/tazobactam will be evaluated in twenty septic patients with renal failure undergoing continuous veno-venous hemodiafiltration. This is a prospective study.

Continuous replacement therapy has a continuous effect on drug elimination which could compromise effective antibiotic treatment.

Patients will receive a standard course of pip/tazo 4g intravenously 8 hourly administrated immediately when CVVHDF will be started.

Blood samples will be collected at 30mn, 2h, 4h, 6h, 8h, 16h, 24h for the first and the second day.

We will measure plasma piperacillin/tazobactam concentration and compare them to MICs for the whole dosing interval.

Enrollment

10 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18 years of age and older .
Females of childbearing potential must have a negative pregnancy test at screening.
Subjects whose life expectancy is estimated over 7 days.
Anuric patients requiring continuous venovenous hemodiafiltration
Septic patients,severe sepsis or septic shock
Written informed consent should be given either by the patient or a member of his family

Exclusion criteria

Subjects with a history of true allergy or adverse drug reactions
Pathogens whose antibiotic susceptibility is not proved.
Patients having impaired hepatic function
Contraindication of anticoagulation by heparin
Residual renal function
Participation in a clinical trial
Interruption of treatment by piper/tazo or hemodiafiltration during the study.
Patients with psychiatric disorder or serious medical condition which in the opinion of the investigator may lead to complexity in patient management.